tetano
Editor, Senior Moderator
Pathogens
. 2022 May 8;11(5):556.
doi: 10.3390/pathogens11050556.
The Multifaceted Manifestations of Multisystem Inflammatory Syndrome during the SARS-CoV-2 Pandemic
Héctor Raúl Pérez-Gómez[SUP] 1 2 [/SUP], Rayo Morfín-Otero[SUP] 1 2 [/SUP], Esteban González-Díaz[SUP] 1 2 3 [/SUP], Sergio Esparza-Ahumada[SUP] 1 2 3 [/SUP], Gerardo León-Garnica[SUP] 1 2 3 [/SUP], Eduardo Rodríguez-Noriega[SUP] 1 2 [/SUP]
Affiliations
Abstract
The novel coronavirus SARS-CoV-2, which has similarities to the 2002-2003 severe acute respiratory syndrome coronavirus known as SARS-CoV-1, causes the infectious disease designated COVID-19 by the World Health Organization (Coronavirus Disease 2019). Although the first reports indicated that activity of the virus is centered in the lungs, it was soon acknowledged that SARS-CoV-2 causes a multisystem disease. Indeed, this new pathogen causes a variety of syndromes, including asymptomatic disease; mild disease; moderate disease; a severe form that requires hospitalization, intensive care, and mechanical ventilation; multisystem inflammatory disease; and a condition called long COVID or postacute sequelae of SARS-CoV-2 infection. Some of these syndromes resemble previously described disorders, including those with no confirmed etiology, such as Kawasaki disease. After recognition of a distinct multisystem inflammatory syndrome in children, followed by a similar syndrome in adults, various multisystem syndromes occurring during the pandemic associated or related to SARS-CoV-2 began to be identified. A typical pattern of cytokine and chemokine dysregulation occurs in these complex syndromes; however, the disorders have distinct immunological determinants that may help to differentiate them. This review discusses the origins of the different trajectories of the inflammatory syndromes related to SARS-CoV-2 infection.
Keywords: COVID-19; MIS-A; MIS-C; PASC; SARS-CoV-2; chemokine abnormalities; coronavirus; cytokine; multisystem inflammatory syndrome.
. 2022 May 8;11(5):556.
doi: 10.3390/pathogens11050556.
The Multifaceted Manifestations of Multisystem Inflammatory Syndrome during the SARS-CoV-2 Pandemic
Héctor Raúl Pérez-Gómez[SUP] 1 2 [/SUP], Rayo Morfín-Otero[SUP] 1 2 [/SUP], Esteban González-Díaz[SUP] 1 2 3 [/SUP], Sergio Esparza-Ahumada[SUP] 1 2 3 [/SUP], Gerardo León-Garnica[SUP] 1 2 3 [/SUP], Eduardo Rodríguez-Noriega[SUP] 1 2 [/SUP]
Affiliations
- PMID: 35631077
- DOI: 10.3390/pathogens11050556
Abstract
The novel coronavirus SARS-CoV-2, which has similarities to the 2002-2003 severe acute respiratory syndrome coronavirus known as SARS-CoV-1, causes the infectious disease designated COVID-19 by the World Health Organization (Coronavirus Disease 2019). Although the first reports indicated that activity of the virus is centered in the lungs, it was soon acknowledged that SARS-CoV-2 causes a multisystem disease. Indeed, this new pathogen causes a variety of syndromes, including asymptomatic disease; mild disease; moderate disease; a severe form that requires hospitalization, intensive care, and mechanical ventilation; multisystem inflammatory disease; and a condition called long COVID or postacute sequelae of SARS-CoV-2 infection. Some of these syndromes resemble previously described disorders, including those with no confirmed etiology, such as Kawasaki disease. After recognition of a distinct multisystem inflammatory syndrome in children, followed by a similar syndrome in adults, various multisystem syndromes occurring during the pandemic associated or related to SARS-CoV-2 began to be identified. A typical pattern of cytokine and chemokine dysregulation occurs in these complex syndromes; however, the disorders have distinct immunological determinants that may help to differentiate them. This review discusses the origins of the different trajectories of the inflammatory syndromes related to SARS-CoV-2 infection.
Keywords: COVID-19; MIS-A; MIS-C; PASC; SARS-CoV-2; chemokine abnormalities; coronavirus; cytokine; multisystem inflammatory syndrome.